

## Correction

---

Reddel HK, Gerhardsson de Verdier M, Agustí A, *et al.* P138 An innovative approach to study design: using electronic medical records to inform the feasibility and design of the novelty study (a novel observational longitudinal study on patients with asthma and/or COPD). *Thorax* 2016;71:A157–A158. doi:10.1136/thoraxjnl-2016-209333.281

The affiliations for some authors has been corrected. The changes are indication in **bold**:

HK Reddel<sup>1</sup>, M Gerhardsson de Verdier<sup>2</sup>, A Agustí<sup>3</sup>, R Beasley<sup>4</sup>, EH Bel<sup>5</sup>, C Janson<sup>6</sup>, B Make<sup>7</sup>, RJ Martin<sup>7</sup>, I Pavord<sup>8</sup>, D Postma<sup>9</sup>, D Price<sup>10</sup>, C Keen<sup>2</sup>, **A Gardev<sup>11</sup>, S Rennard<sup>11</sup>, A Sveréus<sup>2</sup>, AT Bansal<sup>12</sup>, L Brannman<sup>13</sup>, N Karlsson<sup>2</sup>, J Nuevo<sup>14</sup>, F Nyberg<sup>2</sup>, S Young<sup>11</sup>, J Vestbo<sup>15</sup>**

<sup>1</sup>Woolcock Institute of Medical Research, Sydney, Australia

<sup>2</sup>AstraZeneca, Madrid, Spain

<sup>3</sup>Hospital Clinic University of Barcelona, Barcelona, Spain

<sup>4</sup>Medical Research Institute of New Zealand, Wellington, New Zealand

<sup>5</sup>Academic Medical Centre, University of Amsterdam, Amsterdam, The Netherlands

<sup>6</sup>Uppsala University, Uppsala, Sweden

<sup>7</sup>National Jewish Health and University of Colorado, Denver, USA

<sup>8</sup>University of Oxford, Oxford, UK

<sup>9</sup>University of Groningen, University Medical Centre Groningen, Groningen, The Netherlands

<sup>10</sup>Research in Real-Life, Singapore, Singapore

<sup>11</sup>AstraZeneca, Cambridge, UK

<sup>12</sup>Acclarogen Ltd, Cambridge, UK

<sup>13</sup>AstraZeneca, Gaithersburg, MD, USA

<sup>14</sup>AstraZeneca, Madrid, Spain

<sup>15</sup>The University of Manchester, Manchester, UK

*Thorax* 2017;72:235. doi:10.1136/thoraxjnl-2016-209333.281corr1



CrossMark